SCHEMBL267671

SCHEMBL267671

CCN(CC)CCN(CCN(CC)CC)Cc1cccc(C(=O)Nc2sc3c(c2C(=O)N/N=C/c2ccc(OC)cc2)CCCC3)c1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.54
MAPT P10636 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
SLC34A2 O95436 5/20 0.53
FLT3 P36888 2/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NOD1 Q9Y239 1/20 0.51
MGAM O43451 2/20 0.48
AMY1A P0DUB6 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
GLO1 Q04760 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267672 1.00 TP53 (0.54) TP53MAPTSMN1; SMN2SLC34A2FLT3
SCHEMBL273811 0.95 SLC34A2 (0.57) TP53MAPTSMN1; SMN2SLC34A2FLT3
SCHEMBL270095 0.95 SLC34A2 (0.57) TP53MAPTSMN1; SMN2SLC34A2FLT3
SCHEMBL268025 0.94 TP53 (0.51) TP53MAPTSMN1; SMN2SLC34A2FLT3
SCHEMBL268026 0.94 TP53 (0.51) TP53MAPTSMN1; SMN2SLC34A2FLT3
SCHEMBL266920 0.92 SLC34A2 (0.55) TP53MAPTSLC34A2FLT3MEN1
SCHEMBL266919 0.92 SLC34A2 (0.55) TP53MAPTSLC34A2FLT3MEN1
SCHEMBL267351 0.90 TP53 (0.53) TP53MAPTSMN1; SMN2SLC34A2FLT3
SCHEMBL274222 0.90 TP53 (0.53) TP53MAPTSMN1; SMN2SLC34A2FLT3
SCHEMBL267421 0.90 MAPT (0.49) TP53MAPTSMN1; SMN2SLC34A2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 TP53 2556/4885MAPT 4195/4885SMN1; SMN2 3975/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 TP53 2188/4885MAPT 4648/4885SMN1; SMN2 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.